Adverum Biotech
Romu Corbau is currently the Chief Scientific Officer at Adverum Biotechnologies, holding the same title at GenEdit and previously at Freeline. With a background in drug discovery and development, Romu has held various leadership positions in research at companies like Spark Therapeutics, Inc. and Pfizer. Romu holds a Doctor of Philosophy (PhD) from INSERM Unit 375, DKFZ, Heidelberg and has degrees in biochemistry from various universities in France.
This person is not in any offices
Adverum Biotech
9 followers
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.